Significant research funding in the form of a five-year, $12.1 million U19 Grant from the National Institutes of Health (NIH) has been awarded to a collaboration of research teams co-led by ...
Public Health Relevance Statement: Idiopathic Pulmonary Fibrosis (IPF) is fatal lung disorder for which no U.S. FDA-approved drugs currently exist. This project will lead to the development of novel ...
Core Director: Rui-Ming Liu, Ph.D. Idiopathic pulmonary fibrosis (IPF) is a most enigmatic fatal lung disorder. Although significant progress has been made in our understanding of IPF pathogenesis, ...
"Lung cancer remains a devastating disease, and Prof. Yarden's approach to tackling drug resistance with bispecific antibodies is precisely the kind of bold, out-of-the-box science that can transform ...